Mesenbrink P - Search Results

1

Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information.

McTeer M, Applegate D, Mesenbrink P, Ratziu V, Schattenberg JM, Bugianesi E, Geier A, Romero Gomez M, Dufour JF, Ekstedt M, Francque S, Yki-Jarvinen H, Allison M, Valenti L, Miele L, Pavlides M, Cobbold J, Papatheodoridis G, Holleboom AG, Tiniakos D, Brass C, Anstee QM, Missier P; LITMUS Consortium investigators. McTeer M, et al. Among authors: mesenbrink p. PLoS One. 2024 Feb 29;19(2):e0299487. doi: 10.1371/journal.pone.0299487. eCollection 2024. PLoS One. 2024. PMID: 38421999 Free PMC article.

2

Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons.

Pericàs JM, Tacke F, Anstee QM, Di Prospero NA, Kjær MS, Mesenbrink P, Koenig F, Genescà J, Ratziu V; EU-PEARL NASH Investigators. Pericàs JM, et al. Among authors: mesenbrink p. J Hepatol. 2023 Feb;78(2):442-447. doi: 10.1016/j.jhep.2022.09.021. Epub 2022 Oct 8. J Hepatol. 2023. PMID: 36216134 Free article. Review.

3

Risk scoring for time to end-stage knee osteoarthritis: data from the Osteoarthritis Initiative.

Dunn R, Greenhouse J, James D, Ohlssen D, Mesenbrink P. Dunn R, et al. Among authors: mesenbrink p. Osteoarthritis Cartilage. 2020 Aug;28(8):1020-1029. doi: 10.1016/j.joca.2019.12.013. Epub 2020 May 13. Osteoarthritis Cartilage. 2020. PMID: 32416218 Free PMC article.

4

Systematic review of available software for multi-arm multi-stage and platform clinical trial design.

Meyer EL, Mesenbrink P, Mielke T, Parke T, Evans D, König F; EU-PEARL (EU Patient-cEntric clinicAl tRial pLatforms) Consortium. Meyer EL, et al. Among authors: mesenbrink p. Trials. 2021 Mar 4;22(1):183. doi: 10.1186/s13063-021-05130-x. Trials. 2021. PMID: 33663579 Free PMC article. Review.

5

Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials.

Meyer EL, Mesenbrink P, Dunger-Baldauf C, Glimm E, Li Y, König F; EU-PEARL (EU Patient-cEntric clinicAl tRial pLatforms) Consortium. Meyer EL, et al. Among authors: mesenbrink p. Pharm Stat. 2022 May;21(3):671-690. doi: 10.1002/pst.2194. Epub 2022 Jan 31. Pharm Stat. 2022. PMID: 35102685 Free PMC article.

6

A deep-learning-based model for assessment of autoimmune hepatitis from histology: AI(H).

Ercan C, Kordy K, Knuuttila A, Zhou X, Kumar D, Koponen V, Mesenbrink P, Eppenberger-Castori S, Amini P, Pedrosa MC, Terracciano LM. Ercan C, et al. Among authors: mesenbrink p. Virchows Arch. 2024 Dec;485(6):1095-1105. doi: 10.1007/s00428-024-03841-5. Epub 2024 Jun 15. Virchows Arch. 2024. PMID: 38879691 Free PMC article.

7

Regulatory Issues of Platform Trials: Learnings from EU-PEARL.

Nguyen QL, Hees K, Hernandez Penna S, König F, Posch M, Bofill Roig M, Meyer EL, Freitag MM, Parke T, Otte M, Dauben HP, Mielke T, Spiertz C, Mesenbrink P, Gidh-Jain M, Pierre S, Morello S, Hofner B. Nguyen QL, et al. Among authors: mesenbrink p. Clin Pharmacol Ther. 2024 Jul;116(1):52-63. doi: 10.1002/cpt.3244. Epub 2024 Mar 26. Clin Pharmacol Ther. 2024. PMID: 38529786 Review.

8

Developing generic templates to shape the future for conducting integrated research platform trials.

Gidh-Jain M, Parke T, König F, Spiertz C, Mesenbrink P; EU-PEARL (Europe [EU] Patient-cEntric clinicAl tRial pLatforms) an Innovative Medicines Initiative (IMI) initiative Work Package 2 (WP 2). Gidh-Jain M, et al. Among authors: mesenbrink p. Trials. 2024 Mar 21;25(1):204. doi: 10.1186/s13063-024-08034-8. Trials. 2024. PMID: 38515103 Free PMC article.

9

Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL.

Koenig F, Spiertz C, Millar D, Rodríguez-Navarro S, Machín N, Van Dessel A, Genescà J, Pericàs JM, Posch M; EU-PEARL Consortium. Koenig F, et al. EClinicalMedicine. 2023 Dec 26;67:102384. doi: 10.1016/j.eclinm.2023.102384. eCollection 2024 Jan. EClinicalMedicine. 2023. PMID: 38226342 Free PMC article. Review.

10

Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints.

Meyer EL, Mesenbrink P, Di Prospero NA, Pericàs JM, Glimm E, Ratziu V, Sena E, König F; EU-PEARL NASH Investigators. Meyer EL, et al. Among authors: mesenbrink p. PLoS One. 2023 Mar 9;18(3):e0281674. doi: 10.1371/journal.pone.0281674. eCollection 2023. PLoS One. 2023. PMID: 36893087 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

47 results

Search Page

Filters